Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Insight Advisors LLC PA

Insight Advisors LLC PA reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 11.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,503 shares of the medical research company’s stock after selling 192 shares during the period. Insight Advisors LLC PA’s holdings in Thermo Fisher Scientific were worth $1,003,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mizuho Securities Co. Ltd. lifted its stake in shares of Thermo Fisher Scientific by 200.0% in the 3rd quarter. Mizuho Securities Co. Ltd. now owns 45 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 30 shares in the last quarter. Widmann Financial Services Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $26,000. Core Alternative Capital acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $27,000. Lee Financial Co acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $32,000. Finally, Costello Asset Management INC acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $33,000. 86.17% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently commented on TMO. began coverage on Thermo Fisher Scientific in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Wells Fargo & Company lowered Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $605.00 to $525.00 in a research report on Monday, April 25th. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $609.00 price target for the company. in a report on Monday, January 24th. BTIG Research reiterated a “buy” rating and issued a $718.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, February 3rd. Finally, Barclays initiated coverage on Thermo Fisher Scientific in a report on Wednesday, January 26th. They issued an “overweight” rating and a $700.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from, Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $647.00.

In related news, Director Jim P. Manzi sold 1,500 shares of the company’s stock in a transaction on Monday, February 14th. The stock was sold at an average price of $563.95, for a total transaction of $845,925.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.43% of the company’s stock.

Shares of NYSE TMO traded down $5.97 during mid-day trading on Friday, hitting $552.92. 2,168,827 shares of the company traded hands, compared to its average volume of 1,437,132. Thermo Fisher Scientific Inc. has a 1 year low of $438.72 and a 1 year high of $672.34. The stock has a market capitalization of $216.44 billion, a price-to-earnings ratio of 28.83, a PEG ratio of 1.65 and a beta of 0.82. The company has a quick ratio of 1.12, a current ratio of 1.50 and a debt-to-equity ratio of 0.79. The business has a 50 day moving average of $564.76 and a two-hundred day moving average of $597.29.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its earnings results on Thursday, April 28th. The medical research company reported $7.25 EPS for the quarter, beating the consensus estimate of $6.20 by $1.05. Thermo Fisher Scientific had a return on equity of 26.34% and a net margin of 19.70%. The business had revenue of $11.82 billion during the quarter, compared to the consensus estimate of $10.66 billion. During the same period in the prior year, the business posted $7.21 earnings per share. Thermo Fisher Scientific’s revenue was up 19.3% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.54 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, April 14th. Stockholders of record on Wednesday, March 16th were issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 0.22%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.26. The ex-dividend date was Tuesday, March 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.26%.

About Thermo Fisher Scientific (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with's FREE daily email newsletter.